YM 638

Drug Profile

YM 638

Alternative Names: YM 16638

Latest Information Update: 09 Aug 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yamanouchi
  • Class Antiasthmatics; Antiulcers; Cytoprotectives
  • Mechanism of Action Leukotriene D4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Hyperlipidaemia; Peptic ulcer

Most Recent Events

  • 07 May 1999 Phase-I clinical trials for Hyperlipidaemia in Japan (Unknown route)
  • 07 May 1999 A study has been added to the Hyperlipidaemia pharmacodynamics section
  • 30 Jul 1998 No-Development-Reported for Asthma in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top